HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: 2322031157v1 232/2/522    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Topouchian, V. Articles by Penneçot, G.-F. Search for Related Content PubMed PubMed Citation Articles by Topouchian, V. Articles by Penneçot, G.-F.

Aneurysmal Bone Cysts in Children: Complications of Fibrosing Agent Injection¹

¹ From the Department of Orthopedic Surgery, Robert Debré Hospital, 48 bd Sérurier, 75019 Paris, France (V.T., K.M., G.F.P.); and Department of Radiology, Lariboisière Hospital, Paris, France (B.H., J.D.L.). Received July 23, 2003; revision requested October 3; revision received November 12; accepted December 9. Address correspondence to V.T. (e-mail: topouchian.vicken@wanadoo.fr).

PURPOSE: To report complications of direct fibrosing agent injection in the treatment of aneurysmal bone cysts (ABCs) in children.

MATERIALS AND METHODS: The authors retrospectively analyzed all cases of ABCs treated with direct fibrosing agent injection (Ethibloc; Ethnor Laboratories, Ethicon, Noderstedt, Germany) at Robert Debré Hospital since 1994. Histologic diagnosis was assigned by means of surgical biopsy findings prior to treatment. Treatment responses were categorized. Injection was administered with general anesthesia, computed tomographic guidance, and use of a 14- to 16-gauge needle. Contrast material was injected to determine presence of intracystic septa and verify absence of venous opacification. Amount of fibrosing agent injected corresponded to amount of contrast material necessary to fully opacify the cyst. Intraosseous needle track was obliterated with histoacryl injection.

RESULTS: Fifteen patients were treated. Mean follow-up was 80 months; no patient was lost to follow-up. One patient experienced pulmonary embolus that necessitated a 7-day intensive care unit stay. Four patients experienced early aseptic fistulization after the first injection, which led to surgical débridement and curettage. Five patients had transient inflammatory reaction with mild 38°C fever, which was controlled with analgesic and antiinflammatory drugs. Eleven patients did not require surgery, and results at latest follow-up were considered to indicate complete healing (type 1 results) in nine and incomplete healing (type 2 results) in two. For type 1 results: Six patients received one injection, two received two injections, and one received three injections. For type 2 results: one patient received one injection, and one received three injections.

CONCLUSION: A high rate of major local and general complications was encountered with use of direct fibrosing agent injection; the technique has been abandoned for treatment of ABCs.

© RSNA, 2004

Index terms: Bone neoplasms, in infants and children, 40.3183 • Bones, cysts, 40.3183 • Interventional procedures, complications, 40.126

This article has been cited by other articles:

				H. J. Mankin, F. J. Hornicek, E. Ortiz-Cruz, J. Villafuerte, and M. C. Gebhardt Aneurysmal Bone Cyst: A Review of 150 Patients J. Clin. Oncol., September 20, 2005; 23(27): 6756 - 6762. [Abstract] [Full Text] [PDF]

				E. Mascard and C. Adamsbaum Direct Ethibloc Injection of Aneurysmal Bone Cysts Radiology, September 1, 2005; 236(3): 1111 - 1111. [Full Text] [PDF]